Drug Profile
Nicotine inhalation - Aradigm Corporation
Alternative Names: ARD-1600Latest Information Update: 08 Jan 2022
Price :
$50
*
At a glance
- Originator Aradigm Corporation
- Class Alkaloids; Analgesics; Drug withdrawal therapies; Nicotine replacement therapy; Pyridines; Small molecules
- Mechanism of Action Nicotinic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Smoking withdrawal
Most Recent Events
- 28 Dec 2017 No recent reports of development identified for phase-I development in Smoking-withdrawal in USA (Inhalation, Aerosol)
- 23 Dec 2015 Phase-I development is ongoing in USA; programme is still available for licensing
- 10 Sep 2012 Phase-I development is ongoing in USA